Evaluation of the role of EGFR exon 19 747-750 deletion mutation and plasma amino acid profile in the development of lung cancer.
Amino acids
EGFR
Liquid biopsy
Lung cancer
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
04 Oct 2024
04 Oct 2024
Historique:
received:
03
08
2024
accepted:
12
09
2024
medline:
5
10
2024
pubmed:
5
10
2024
entrez:
4
10
2024
Statut:
epublish
Résumé
Lung cancer (LC) is the most common form of cancer in the world. Of the proteins involved in cell differentiation and proliferation, the epidermal growth factor receptor (EGFR) is among the most significant. Amino acids play a crucial role in cell physiology as metabolic regulators. The benefits of liquid biopsies are their non-invasive nature, ease of collection, and ability to depict the entire tumor's status. The present study is designed to detect the relation between the EGFR exon 19 747-750 deletion mutation and lung cancer and investigate the patterns of alterations of plasma-free amino acids (PFAA) in lung cancer patients of different histopathological types and stages as biomarkers for early detection of lung cancer. The study sample comprised 60 lung cancer patients and 60 age- and sex-matched healthy individuals as the control group. Polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) were used to examine the EGFR exon 19 747-750 deletion mutation, and an AA analyzer was used to quantify the plasma free amino acid (PFAA) profile. Compared with controls, LC patients had significantly higher levels of three AAs and significantly lower levels of fifteen AAs. Thirteen AAs varied significantly between stages I and II. In the lung cancer group, the percentage of cases of mutant EGFR exon-19 deletion increased to 30% from 13.3% in the control group. The histological forms of lung cancer did not significantly differ in this rise. Valine and citrulline plasma levels were substantially greater in the mutant than in the wild-type. Lysine, histidine, and methionine were the independent predictors of the LC group in multivariate analysis. Lung cancer development is influenced by the EGFR exon 19 747-750 deletion mutation, and the prognosis and early prediction of lung cancer are greatly affected by the amino acid profile concentrations.
Sections du résumé
BACKGROUND
BACKGROUND
Lung cancer (LC) is the most common form of cancer in the world. Of the proteins involved in cell differentiation and proliferation, the epidermal growth factor receptor (EGFR) is among the most significant. Amino acids play a crucial role in cell physiology as metabolic regulators. The benefits of liquid biopsies are their non-invasive nature, ease of collection, and ability to depict the entire tumor's status. The present study is designed to detect the relation between the EGFR exon 19 747-750 deletion mutation and lung cancer and investigate the patterns of alterations of plasma-free amino acids (PFAA) in lung cancer patients of different histopathological types and stages as biomarkers for early detection of lung cancer.
METHODS
METHODS
The study sample comprised 60 lung cancer patients and 60 age- and sex-matched healthy individuals as the control group. Polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) were used to examine the EGFR exon 19 747-750 deletion mutation, and an AA analyzer was used to quantify the plasma free amino acid (PFAA) profile.
RESULTS
RESULTS
Compared with controls, LC patients had significantly higher levels of three AAs and significantly lower levels of fifteen AAs. Thirteen AAs varied significantly between stages I and II. In the lung cancer group, the percentage of cases of mutant EGFR exon-19 deletion increased to 30% from 13.3% in the control group. The histological forms of lung cancer did not significantly differ in this rise. Valine and citrulline plasma levels were substantially greater in the mutant than in the wild-type. Lysine, histidine, and methionine were the independent predictors of the LC group in multivariate analysis.
CONCLUSION
CONCLUSIONS
Lung cancer development is influenced by the EGFR exon 19 747-750 deletion mutation, and the prognosis and early prediction of lung cancer are greatly affected by the amino acid profile concentrations.
Identifiants
pubmed: 39367097
doi: 10.1007/s11033-024-09941-4
pii: 10.1007/s11033-024-09941-4
doi:
Substances chimiques
ErbB Receptors
EC 2.7.10.1
EGFR protein, human
EC 2.7.10.1
Amino Acids
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1039Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A (2021) Epidemiology of lung cancer. Contem Oncol (Poznan, Poland) 25:45–52
Khodabakhshi Z, Mostafaei S, Arabi H, Oveisi M, Shiri I, Zaidi H (2021) Non-small cell lung carcinoma histopathological subtype phenotyping using high-dimensional multinomial multiclass CT radiomics signature. Comput Biol Med 136:104752
doi: 10.1016/j.compbiomed.2021.104752
pubmed: 34391002
Chen P, Liu Y, Wen Y, Zhou C (2022) Non-small cell lung cancer in China. Cancer Commun (Lond, Eng) 42:937–970
doi: 10.1002/cac2.12359
Li W, Liu JB, Hou LK, Yu F, Zhang J, Wu W, Tang XM, Sun F, Lu HM, Deng J, Bai J, Li J, Wu CY, Lin QL, Lv ZW, Wang GR, Jiang GX, Ma YS, Fu D (2022) Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring. Mol Cancer 21:25
doi: 10.1186/s12943-022-01505-z
pubmed: 35057806
pmcid: 8772097
Casagrande GMS, Silva MO, Reis RM, Leal LF (2023) Liquid biopsy for lung cancer: up-to-date and perspectives for screening programs. Int J Mol Sci 24:25055
doi: 10.3390/ijms24032505
Macdonald-Obermann JL, Pike LJ (2024) Extracellular domain mutations of the EGF receptor differentially modulate high-affinity and low-affinity responses to EGF receptor ligands. J Biol Chem 300:105763
doi: 10.1016/j.jbc.2024.105763
pubmed: 38367671
pmcid: 10945275
Rybarczyk-Kasiuchnicz A, Ramlau R, Stencel K (2021) Treatment of brain metastases of non-small cell lung carcinoma. Int J Mol Sci 22:593
doi: 10.3390/ijms22020593
pubmed: 33435596
pmcid: 7826874
Xie Y, Meng WY, Li RZ, Wang YW, Qian X, Chan C, Yu ZF, Fan XX, Pan HD, Xie C, Wu QB, Yan PY, Liu L, Tang YJ, Yao XJ, Wang MF, Leung EL (2021) Early lung cancer diagnostic biomarker discovery by machine learning methods. Translational oncology 14:100907
doi: 10.1016/j.tranon.2020.100907
pubmed: 33217646
Saha, S., Ghosh, M., (2024) The role of one-carbon amino acids in tumor-immune metabolism: From oncogenesis to therapy, Elsevier, pp. 51–68.
Varzieva VG, Mesonzhnik NV, Ilgisonis IS, Belenkov YN, Kozhevnikova MV, Appolonova SA (2024) Metabolomic biomarkers of multiple myeloma: a systematic review. Biochimica et Biophysica Acta (BBA)-Rev Cancer. https://doi.org/10.1016/j.bbcan.2024.189151
doi: 10.1016/j.bbcan.2024.189151
Leela-Arporn R, Ohta H, Tamura M, Nagata N, Sasaoka K, Dermlim A, Nisa K, Osuga T, Morishita K, Sasaki N, Takiguchi M (2019) Plasma-free amino acid profiles in dogs with hepatocellular carcinoma. J Vet Intern Med 33:1653–1659
doi: 10.1111/jvim.15512
pubmed: 31066966
pmcid: 6639499
Wei Z, Liu X, Cheng C, Yu W, Yi P (2020) Metabolism of amino acids in cancer. Frontiers in cell and developmental biology 8:603837
doi: 10.3389/fcell.2020.603837
pubmed: 33511116
Liu K, Li J, Long T, Wang Y, Yin T, Long J, Shen Y, Cheng L (2022) Changes in serum amino acid levels in non-small cell lung cancer: a case-control study in Chinese population. PeerJ 10:e13272
doi: 10.7717/peerj.13272
pubmed: 35469201
pmcid: 9034703
Ertural DY, Nayir E, Arpaci RB, Eker ED, Nazan E, Yildirim DD, Akbaş E (2019) The effects of EGFR exon 19 747–750 deletion on the risk of developing lung cancer. Med Sci Dis 6:109–113
doi: 10.17546/msd.569279
Bidzińska J, Szurowska E (2023) See lung cancer with an AI. Cancers 15:1321
doi: 10.3390/cancers15041321
pubmed: 36831662
pmcid: 9954317
Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, Mukherjee A, Paul MK (2023) Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer 22:1–37
doi: 10.1186/s12943-023-01740-y
Chinnappan R, Mir TA, Alsalameh S, Makhzoum T, Alzhrani A, Alnajjar K, Adeeb S, Al Eman N, Ahmed Z, Shakir I (2023) Emerging biosensing methods to monitor lung cancer biomarkers in biological samples: a comprehensive review. Cancers 15:3414
doi: 10.3390/cancers15133414
pubmed: 37444523
pmcid: 10341261
Jouida A, McCarthy C, Fabre A, Keane MP (2021) Exosomes: a new perspective in EGFR-mutated lung cancer. Cancer Metastasis Rev 40:589–601
doi: 10.1007/s10555-021-09962-6
pubmed: 33855679
pmcid: 8213600
Ciardiello F, Hirsch FR, Pirker R, Felip E, Valencia C, Smit EF (2023) The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer. Cancer Treat Rev. https://doi.org/10.1016/j.ctrv.2023.102664
doi: 10.1016/j.ctrv.2023.102664
pubmed: 38064878
Basolo, A., Matrone, A., Elisei, R., Santini, F., Elsevier, pp. 197–202.
Truini A, Starrett JH, Stewart T, Ashtekar K, Walther Z, Wurtz A, Lu D, Park JH, DeVeaux M, Song X, Gettinger S, Zelterman D, Lemmon MA, Goldberg SB, Politi K (2019) The EGFR exon 19 mutant L747–A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma. Clinl Cancer Res: Off J Am Assoc Cancer Res 25:6382–6391
doi: 10.1158/1078-0432.CCR-19-0780
Xu CW, Lei L, Wang WX, Lin L, Zhu YC, Wang H, Miao LY, Wang LP, Zhuang W, Fang MY, Lv TF, Song Y (2020) Molecular characteristics and clinical outcomes of EGFR exon 19 C-helix deletion in non-small cell lung cancer and response to EGFR TKIs. Transl Oncol 13:100791
doi: 10.1016/j.tranon.2020.100791
pubmed: 32492620
pmcid: 7264750
van de Geer WS, Hoogstrate Y, Draaisma K, Robe PA, Bins S, Mathijssen RHJ, French P, van de Werken HJG, de Vos FYF (2022) Landscape of driver gene events, biomarkers, and druggable targets identified by whole-genome sequencing of glioblastomas. Neuro Oncol Adv. https://doi.org/10.1093/noajnl/vdab177
doi: 10.1093/noajnl/vdab177
Le T, Gerber DE (2019) Newer-generation EGFR inhibitors in lung cancer: how are they best used? Cancers 11:366
doi: 10.3390/cancers11030366
pubmed: 30875928
pmcid: 6468595
Whi W, Ha S, Bae S, Choi H, Paeng JC, Cheon GJ, Kang KW, Lee DS (2020) Relationship of EGFR mutation to glucose metabolic activity and asphericity of metabolic tumor volume in lung adenocarcinoma. Nucl Med Mol Imaging 54:175–182
doi: 10.1007/s13139-020-00646-7
pubmed: 32831963
pmcid: 7429575
Hellyer JA, White MN, Gardner RM, Cunanan K, Padda SK, Das M, Ramchandran K, Neal JW, Wakelee HA (2022) Impact of tumor suppressor gene co-mutations on differential response to EGFR TKI therapy in EGFR L858R and Exon 19 deletion lung cancer. Clin Lung Cancer 23:264–272
doi: 10.1016/j.cllc.2021.09.004
pubmed: 34838441
Jin R, Peng L, Shou J, Wang J, Jin Y, Liang F, Zhao J, Wu M, Li Q, Zhang B (2021) EGFR-mutated squamous cell lung cancer and its association with outcomes. Front Oncol 11:680804
doi: 10.3389/fonc.2021.680804
pubmed: 34195081
pmcid: 8236808
Yoon H-Y, Ryu J-S, Sim YS, Kim D, Lee SY, Choi J, Park S, Ryu YJ, Lee JH, Chang JH (2020) Clinical significance of EGFR mutation types in lung adenocarcinoma: a multi-centre Korean study. PLoS ONE 15:e0228925
doi: 10.1371/journal.pone.0228925
pubmed: 32053675
pmcid: 7018076
Brown BP, Zhang Y-K, Kim S, Finneran P, Yan Y, Du Z, Kim J, Hartzler AL, LeNoue-Newton ML, Smith AW (2022) Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer. Proc Natl Acad Sci 119:e2206588119
doi: 10.1073/pnas.2206588119
pubmed: 35867821
pmcid: 9335329
Zhang C, Wang Y, Cao Y, Shi L, Wang R, Sheng N, Wang Q, Zhu Z (2022) Study on plasma amino acids and piperonamide as potential diagnostic biomarkers of non-small cell lung cancer. Trans Cancer Res 11:1269–1284
doi: 10.21037/tcr-22-865
Eltayeb K, La Monica S, Tiseo M, Alfieri R, Fumarola C (2022) Reprogramming of lipid metabolism in lung cancer: an overview with focus on EGFR-mutated non-small cell lung cancer. Cells 11:413
doi: 10.3390/cells11030413
pubmed: 35159223
pmcid: 8834094
Belskaya LV, Sarf EA, Loginova AI (2023) Diagnostic value of salivary amino acid levels in cancer. Metabolites 13:950
doi: 10.3390/metabo13080950
pubmed: 37623893
Madama D, Martins R, Pires AS, Botelho MF, Alves MG, Abrantes AM, Cordeiro CR (2021) Metabolomic profiling in lung cancer: a systematic review. Metabolites 11:630
doi: 10.3390/metabo11090630
pubmed: 34564447
pmcid: 8471464
Namikawa-Kanai H, Miyazaki T, Matsubara T, Shigefuku S, Ono S, Nakajima E, Morishita Y, Honda A, Furukawa K, Ikeda N (2020) Comparison of the amino acid profile between the nontumor and tumor regions in patients with lung cancer. Am J Cancer Res 10:2145
pubmed: 32775007
pmcid: 7407354
Kim KS, Moon SW, Moon MH, Hyun KY, Kim SJ, Kim YK, Kim KY, Jekarl DW, Oh EJ, Kim Y (2023) Metabolic profiles of lung adenocarcinoma via peripheral blood and diagnostic model construction. Sci Rep 13:7304
doi: 10.1038/s41598-023-34575-0
pubmed: 37147444
pmcid: 10163250
Ni J, Xu L, Li W, Zheng C, Wu L (2019) Targeted metabolomics for serum amino acids and acylcarnitines in patients with lung cancer. Exp Ther Med 18:188–198
pubmed: 31258653
pmcid: 6566041
Kowalczyk T, Kisluk J, Pietrowska K, Godzien J, Kozlowski M, Reszeć J, Sierko E, Naumnik W, Mróz R, Moniuszko M, Kretowski A, Niklinski J, Ciborowski M (2021) The ability of metabolomics to discriminate non-small-cell lung cancer subtypes depends on the stage of the disease and the type of material studied. Cancers 13:3314
doi: 10.3390/cancers13133314
pubmed: 34282765
pmcid: 8268630
Amelia T, Kartasasmita RE, Ohwada T, Tjahjono DH (2022) structural insight and development of EGFR tyrosine kinase inhibitors. Molecules 27:819
doi: 10.3390/molecules27030819
pubmed: 35164092
pmcid: 8838133
Colella B, Colardo M, Iannone G, Contadini C, Saiz-Ladera C, Fuoco C, Barilà D, Velasco G, Segatto M, Di Bartolomeo S (2020) mTOR inhibition leads to src-mediated EGFR internalisation and degradation in glioma cells. Cancers 12:2266
doi: 10.3390/cancers12082266
pubmed: 32823532
pmcid: 7464593
Tan Y, Chrysopoulou M, Rinschen MM (2023) Integrative physiology of lysine metabolites. Physiol Genomics 55:579–586
doi: 10.1152/physiolgenomics.00061.2023
pubmed: 37781739
Holeček M (2020) Histidine in health and disease: metabolism, physiological importance, and use as a supplement. Nutrients 12:848
doi: 10.3390/nu12030848
pubmed: 32235743
pmcid: 7146355
Lauinger L, Kaiser P (2021) Sensing and signaling of methionine metabolism. Metabolites 11:83
doi: 10.3390/metabo11020083
pubmed: 33572567
pmcid: 7912243
Tang Q, Tan P, Ma N, Ma X (2021) Physiological functions of threonine in animals: beyond nutrition metabolism. Nutrients 13:2592
doi: 10.3390/nu13082592
pubmed: 34444752
pmcid: 8399342